Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
—·19h
South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group.
ChannelsstocksCountriesusa, koreaCategoriesmergers-acquisitions
Open original source ↗Published
7/20/2026, 2:56:00 AM
Fetched
7/20/2026, 3:07:23 AM
Confidence
60 / 100
Relevance
44 / 100
Trust
—
Language
en